US 11,701,347 B2
Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
Arne Scholz, Berlin (DE)
Assigned to BAYER AKTIENGESELLSCHAFT, Leverkusen (DE); and BAYER PHARMA AKTIENGESELLSCHAFT, Berlin (DE)
Appl. No. 16/969,460
Filed by Bayer Aktiengesellschaft, Leverkusen (DE); and Bayer Pharma Aktiengesellschaft, Berlin (DE)
PCT Filed Feb. 12, 2019, PCT No. PCT/EP2019/053407
§ 371(c)(1), (2) Date Aug. 12, 2020,
PCT Pub. No. WO2019/158517, PCT Pub. Date Aug. 22, 2019.
Claims priority of application No. 18156576 (EP), filed on Feb. 13, 2018.
Prior Publication US 2021/0015806 A1, Jan. 21, 2021
Int. Cl. A61K 31/444 (2006.01); A61P 35/00 (2006.01); A61K 31/53 (2006.01)
CPC A61K 31/444 (2013.01) [A61K 31/53 (2013.01); A61P 35/00 (2018.01)] 9 Claims
 
1. A method of treatment and/or prophylaxis of diffuse large B-cell lymphoma, comprising administering an effective amount of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine of formula I or a physiologically acceptable salt or enantiomer thereof to a patient in need thereof

OG Complex Work Unit Chemistry
wherein the diffuse large B-cell lymphoma is a diffuse large B-cell lymphoma which cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or an overexpression of the BCL2 protein.